9.57 -0.1 (-1.03%) | 04-17 11:23 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 11.37 | 1-year : | 13.28 |
Resists | First : | 9.73 | Second : | 11.37 |
Pivot price | 9.25 | |||
Supports | First : | 8.67 | Second : | 8.02 |
MAs | MA(5) : | 9.57 | MA(20) : | 9.05 |
MA(100) : | 8.63 | MA(250) : | 9.26 | |
MACD | MACD : | 0.3 | Signal : | 0.2 |
%K %D | K(14,3) : | 88.5 | D(3) : | 89.1 |
RSI | RSI(14): 63.3 | |||
52-week | High : | 13.13 | Low : | 7.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DXR ] has closed below upper band by 29.1%. Bollinger Bands are 3.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 9.75 - 9.81 | 9.81 - 9.86 |
Low: | 9.4 - 9.48 | 9.48 - 9.54 |
Close: | 9.45 - 9.55 | 9.55 - 9.65 |
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Wed, 17 Apr 2024
Daxor announces two new studies on BVA - TipRanks.com - TipRanks
Mon, 15 Apr 2024
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR - GlobeNewswire
Thu, 28 Mar 2024
Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript - Yahoo Finance UK
Mon, 25 Mar 2024
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance ... - GlobeNewswire
Mon, 18 Mar 2024
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of ... - Yahoo Finance Australia
Mon, 18 Mar 2024
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Instruments & Supplies
|
|
Shares Out | 5 (M) |
Shares Float | 2 (M) |
Held by Insiders | 57 (%) |
Held by Institutions | 1.5 (%) |
Shares Short | 7 (K) |
Shares Short P.Month | 7 (K) |
EPS | 0.14 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 7.07 |
Profit Margin | 171.7 % |
Operating Margin | -511.4 % |
Return on Assets (ttm) | -1.6 % |
Return on Equity (ttm) | 0.8 % |
Qtrly Rev. Growth | -14.5 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.03 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -57.6 % |
Operating Cash Flow | -4 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 68.35 |
PEG Ratio | 0 |
Price to Book value | 1.35 |
Price to Sales | 281.67 |
Price to Cash Flow | -12.58 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |